News
Aavantgarde Presents Safety Data Of The First Two Subjects Dosed In The LUCE-1 Study, Evaluating AAVB-081 (Dual-AAV) In Retinitis Pigmentosa Related To Usher Syndrome Type 1B At Floretina 2024
(MENAFN - GlobeNewsWire - Nasdaq) MILAN, Dec. 09, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, presented preliminary safety data on the first ...
By: menafn
- Dec 09 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS